Loading…
Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke
Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between M...
Saved in:
Published in: | Journal of stroke and cerebrovascular diseases 2017-04, Vol.26 (4), p.733-740 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83 |
---|---|
cites | cdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83 |
container_end_page | 740 |
container_issue | 4 |
container_start_page | 733 |
container_title | Journal of stroke and cerebrovascular diseases |
container_volume | 26 |
creator | Abdelnaseer, Maged M., MD Elfauomy, Nervana M., MD Esmail, Eman H., MD Kamal, Manal M., MD Elsawy, Enji H., MSc |
description | Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery. |
doi_str_mv | 10.1016/j.jstrokecerebrovasdis.2016.09.043 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1856867807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1052305716303743</els_id><sourcerecordid>1856867807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</originalsourceid><addsrcrecordid>eNqVkU1v1DAQhi1URD_gL6AcUaUETxwn9gW1XZVSaSskCmfLmUyE02zc2smK_fd42cIBceE0lubVM-NnGDsHXgCH-v1QDHEO_oGQArXBb23sXCzK1Cu4LnglXrATkKLMlQQ4Sm8uy1xw2Ryz0xgHzgGkkq_Ycal4LZoGTtjFnZ2D-5Hd0WzH0T8GP5ObbKRcZ3bqsi-Efkthl_k-u8Rlpuw24nfaOMzuf-3ymr3s7RjpzXM9Y98-Xn9dfcrXn29uV5frHCup57zqmrYHoh4qLStFnYZGYqulEqCVQC1LTqKuS12rXgnCFrCzirdSqBJRiTP27sBNKz4tFGezcRFpHO1EfokGlKxV3SjepOjVIYrBxxioN4_BbWzYGeBmb9IM5l8mzd6k4dokkwny9nne0m6o-4P4rS4F1ocApV9vHQUT0dGE1LlAOJvOu_-b9-EvHI5ucmjHB9pRHPwSpuTXgIml4eZ-f9v9aaEWXDQJ8BOrvKdI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1856867807</pqid></control><display><type>article</type><title>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Abdelnaseer, Maged M., MD ; Elfauomy, Nervana M., MD ; Esmail, Eman H., MD ; Kamal, Manal M., MD ; Elsawy, Enji H., MSc</creator><creatorcontrib>Abdelnaseer, Maged M., MD ; Elfauomy, Nervana M., MD ; Esmail, Eman H., MD ; Kamal, Manal M., MD ; Elsawy, Enji H., MSc</creatorcontrib><description>Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.</description><identifier>ISSN: 1052-3057</identifier><identifier>EISSN: 1532-8511</identifier><identifier>DOI: 10.1016/j.jstrokecerebrovasdis.2016.09.043</identifier><identifier>PMID: 28063771</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Brain Ischemia - complications ; Cardiovascular ; Case-Control Studies ; Female ; Humans ; Male ; Matrix metalloproteinase ; Matrix Metalloproteinase 9 - blood ; Middle Aged ; modified Rankin Scale ; Neurology ; NIHSS ; outcome ; predictor ; recovery ; Recovery of Function - physiology ; Severity of Illness Index ; Statistics as Topic ; stroke ; Stroke - blood ; Stroke - etiology</subject><ispartof>Journal of stroke and cerebrovascular diseases, 2017-04, Vol.26 (4), p.733-740</ispartof><rights>National Stroke Association</rights><rights>2017 National Stroke Association</rights><rights>Copyright © 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</citedby><cites>FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28063771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelnaseer, Maged M., MD</creatorcontrib><creatorcontrib>Elfauomy, Nervana M., MD</creatorcontrib><creatorcontrib>Esmail, Eman H., MD</creatorcontrib><creatorcontrib>Kamal, Manal M., MD</creatorcontrib><creatorcontrib>Elsawy, Enji H., MSc</creatorcontrib><title>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</title><title>Journal of stroke and cerebrovascular diseases</title><addtitle>J Stroke Cerebrovasc Dis</addtitle><description>Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.</description><subject>Aged</subject><subject>Brain Ischemia - complications</subject><subject>Cardiovascular</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Middle Aged</subject><subject>modified Rankin Scale</subject><subject>Neurology</subject><subject>NIHSS</subject><subject>outcome</subject><subject>predictor</subject><subject>recovery</subject><subject>Recovery of Function - physiology</subject><subject>Severity of Illness Index</subject><subject>Statistics as Topic</subject><subject>stroke</subject><subject>Stroke - blood</subject><subject>Stroke - etiology</subject><issn>1052-3057</issn><issn>1532-8511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqVkU1v1DAQhi1URD_gL6AcUaUETxwn9gW1XZVSaSskCmfLmUyE02zc2smK_fd42cIBceE0lubVM-NnGDsHXgCH-v1QDHEO_oGQArXBb23sXCzK1Cu4LnglXrATkKLMlQQ4Sm8uy1xw2Ryz0xgHzgGkkq_Ycal4LZoGTtjFnZ2D-5Hd0WzH0T8GP5ObbKRcZ3bqsi-Efkthl_k-u8Rlpuw24nfaOMzuf-3ymr3s7RjpzXM9Y98-Xn9dfcrXn29uV5frHCup57zqmrYHoh4qLStFnYZGYqulEqCVQC1LTqKuS12rXgnCFrCzirdSqBJRiTP27sBNKz4tFGezcRFpHO1EfokGlKxV3SjepOjVIYrBxxioN4_BbWzYGeBmb9IM5l8mzd6k4dokkwny9nne0m6o-4P4rS4F1ocApV9vHQUT0dGE1LlAOJvOu_-b9-EvHI5ucmjHB9pRHPwSpuTXgIml4eZ-f9v9aaEWXDQJ8BOrvKdI</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Abdelnaseer, Maged M., MD</creator><creator>Elfauomy, Nervana M., MD</creator><creator>Esmail, Eman H., MD</creator><creator>Kamal, Manal M., MD</creator><creator>Elsawy, Enji H., MSc</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</title><author>Abdelnaseer, Maged M., MD ; Elfauomy, Nervana M., MD ; Esmail, Eman H., MD ; Kamal, Manal M., MD ; Elsawy, Enji H., MSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Brain Ischemia - complications</topic><topic>Cardiovascular</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Middle Aged</topic><topic>modified Rankin Scale</topic><topic>Neurology</topic><topic>NIHSS</topic><topic>outcome</topic><topic>predictor</topic><topic>recovery</topic><topic>Recovery of Function - physiology</topic><topic>Severity of Illness Index</topic><topic>Statistics as Topic</topic><topic>stroke</topic><topic>Stroke - blood</topic><topic>Stroke - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelnaseer, Maged M., MD</creatorcontrib><creatorcontrib>Elfauomy, Nervana M., MD</creatorcontrib><creatorcontrib>Esmail, Eman H., MD</creatorcontrib><creatorcontrib>Kamal, Manal M., MD</creatorcontrib><creatorcontrib>Elsawy, Enji H., MSc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of stroke and cerebrovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelnaseer, Maged M., MD</au><au>Elfauomy, Nervana M., MD</au><au>Esmail, Eman H., MD</au><au>Kamal, Manal M., MD</au><au>Elsawy, Enji H., MSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</atitle><jtitle>Journal of stroke and cerebrovascular diseases</jtitle><addtitle>J Stroke Cerebrovasc Dis</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>26</volume><issue>4</issue><spage>733</spage><epage>740</epage><pages>733-740</pages><issn>1052-3057</issn><eissn>1532-8511</eissn><abstract>Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28063771</pmid><doi>10.1016/j.jstrokecerebrovasdis.2016.09.043</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1052-3057 |
ispartof | Journal of stroke and cerebrovascular diseases, 2017-04, Vol.26 (4), p.733-740 |
issn | 1052-3057 1532-8511 |
language | eng |
recordid | cdi_proquest_miscellaneous_1856867807 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Aged Brain Ischemia - complications Cardiovascular Case-Control Studies Female Humans Male Matrix metalloproteinase Matrix Metalloproteinase 9 - blood Middle Aged modified Rankin Scale Neurology NIHSS outcome predictor recovery Recovery of Function - physiology Severity of Illness Index Statistics as Topic stroke Stroke - blood Stroke - etiology |
title | Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A18%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Matrix%20Metalloproteinase-9%20and%20Recovery%20of%20Acute%20Ischemic%20Stroke&rft.jtitle=Journal%20of%20stroke%20and%20cerebrovascular%20diseases&rft.au=Abdelnaseer,%20Maged%20M.,%20MD&rft.date=2017-04-01&rft.volume=26&rft.issue=4&rft.spage=733&rft.epage=740&rft.pages=733-740&rft.issn=1052-3057&rft.eissn=1532-8511&rft_id=info:doi/10.1016/j.jstrokecerebrovasdis.2016.09.043&rft_dat=%3Cproquest_cross%3E1856867807%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1856867807&rft_id=info:pmid/28063771&rfr_iscdi=true |